Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gh Research Plc (GHRS)
:GHRS
GHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.00 - $20.50
Previous CloseN/A
Volume14.35K
Average Volume (3M)749.48K
Market Cap
$868.70M
Enterprise Value$198.76M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Feb 27, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding62,028,145
10 Day Avg. Volume449,442
30 Day Avg. Volume749,476
Standard Deviation0.20
R-Squared0.05
Alpha-0.00598
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-631.00
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$32.25Price Target Upside130.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessGH Research announced positive top-line results from its Phase 2b trial with its lead candidate GH001 for treatment-resistant depression, indicating significant improvement in depression symptoms.
Regulatory AdvancementThe Phase 2b data are supportive of advancement to Phase 3 development for GH001.
Revenue PotentialGH001 may generate peak annual revenues of over $1B in treatment-resistant depression alone if approved.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to GH001, GH002, and GH003, competitor risk, government regulatory risk, capital market and dilution risk, commercialization risk, reimbursement risk, pricing risk, and business development risk.
Regulatory ChallengesGH has completed all non-clinical inhalation toxicology studies requested by the FDA to address the Investigational New Drug (IND) hold for GH001 administration via its novel aerosol delivery device.
Trial LimitationsAll prior results have been in small, open-label datasets, which means the ph2b placebo-controlled readout will be the first true test for GH001.
---
Ownership Overview
―
Insiders
2.21% Mutual Funds
43.06% Other Institutional Investors
54.54% Public Companies and Individual Investors
GHRS FAQ
What was Gh Research Plc’s price range in the past 12 months?
Gh Research Plc lowest stock price was $6.00 and its highest was $20.50 in the past 12 months.
What is Gh Research Plc’s market cap?
Gh Research Plc’s market cap is $868.70M.
When is Gh Research Plc’s upcoming earnings report date?
Gh Research Plc’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Gh Research Plc’s earnings last quarter?
Gh Research Plc released its earnings results on Nov 14, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.016.
Is Gh Research Plc overvalued?
According to Wall Street analysts Gh Research Plc’s price is currently Undervalued.
Does Gh Research Plc pay dividends?
Gh Research Plc does not currently pay dividends.
What is Gh Research Plc’s EPS estimate?
Gh Research Plc’s EPS estimate is -0.23.
How many shares outstanding does Gh Research Plc have?
Gh Research Plc has 62,028,145 shares outstanding.
What happened to Gh Research Plc’s price movement after its last earnings report?
Gh Research Plc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -2.922%.
Which hedge fund is a major shareholder of Gh Research Plc?
Currently, no hedge funds are holding shares in GHRS
---
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.25 (130.36% Upside)
$32.25 (130.36% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 32.6%
Last 30 Days ▲ 32.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.43%
12-Months-Change
Fundamentals
Return on Equity
-19.96%
Trailing 12-Months
Asset Growth
-14.17%
Trailing 12-Months
Company Description
Gh Research Plc
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
---
GHRS Stock 12 Month Forecast
Average Price Target
$32.25
▲(130.36% Upside)
Technical Analysis
Best Analysts Covering GHRS
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+16.25%
reiterated a buy rating 17 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +16.25% per trade.
---